Toward precision medicine for preserving fertility in cancer patients: Existing and emerging fertility preservation options for women

So Youn Kim, Seul Ki Kim, Jung Ryeol Lee, Teresa K. Woodruff

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

As the number of young cancer survivors increases, quality of life after cancer treatment is becoming an ever more important consideration. According to a report from the American Cancer Society, approximately 810,170 women were diagnosed with cancer in 2015 in the United States. Among female cancer survivors, 1 in 250 are of reproductive age. Anticancer therapies can result in infertility or sterility and can have long-term negative effects on bone health, cardiovascular health as a result of reproductive endocrine function. Fertility preservation has been identified by many young patients diagnosed with cancer as second only to survival in terms of importance. The development of fertility preservation technologies aims to help patients diagnosed with cancer to preserve or protect their fertility prior to exposure to chemo- or radiation therapy, thus improving their chances of having a family and enhancing their quality of life as a cancer survivor. Currently, sperm, egg, and embryo banking are standard of care for preserving fertility for reproductive-age cancer patients; ovarian tissue cryopreservation is still considered experimental. Adoption and surrogate may also need to be considered. All patients should receive information about the fertility risks associated with their cancer treatment and the fertility preservation options available in a timely manner, whether or not they decide to ultimately pursue fertility preservation. Because of the ever expanding number of options for treating cancer and preserving fertility, there is now an opportunity to take a precision medicine approach to informing patients about the fertility risks associated with their cancer treatment and the fertility preservation options that are available to them.

Original languageEnglish (US)
JournalJournal of Gynecologic Oncology
Volume27
Issue number2
DOIs
StatePublished - Mar 2016

Fingerprint

Fertility Preservation
Precision Medicine
Fertility
Neoplasms
Survivors
Infertility
Quality of Life
Second Primary Neoplasms
Cryopreservation
Health
Therapeutics
Standard of Care
Ovum
Spermatozoa
Radiotherapy
Embryonic Structures

Keywords

  • Cancer
  • Chemo- or radiation therapy
  • Fertility preservation
  • Oocyte
  • Precision medicine
  • Technologies

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Toward precision medicine for preserving fertility in cancer patients : Existing and emerging fertility preservation options for women. / Kim, So Youn; Kim, Seul Ki; Lee, Jung Ryeol; Woodruff, Teresa K.

In: Journal of Gynecologic Oncology, Vol. 27, No. 2, 03.2016.

Research output: Contribution to journalReview article

@article{2e249eb30c3a41e3a45be1f7d0d4cd73,
title = "Toward precision medicine for preserving fertility in cancer patients: Existing and emerging fertility preservation options for women",
abstract = "As the number of young cancer survivors increases, quality of life after cancer treatment is becoming an ever more important consideration. According to a report from the American Cancer Society, approximately 810,170 women were diagnosed with cancer in 2015 in the United States. Among female cancer survivors, 1 in 250 are of reproductive age. Anticancer therapies can result in infertility or sterility and can have long-term negative effects on bone health, cardiovascular health as a result of reproductive endocrine function. Fertility preservation has been identified by many young patients diagnosed with cancer as second only to survival in terms of importance. The development of fertility preservation technologies aims to help patients diagnosed with cancer to preserve or protect their fertility prior to exposure to chemo- or radiation therapy, thus improving their chances of having a family and enhancing their quality of life as a cancer survivor. Currently, sperm, egg, and embryo banking are standard of care for preserving fertility for reproductive-age cancer patients; ovarian tissue cryopreservation is still considered experimental. Adoption and surrogate may also need to be considered. All patients should receive information about the fertility risks associated with their cancer treatment and the fertility preservation options available in a timely manner, whether or not they decide to ultimately pursue fertility preservation. Because of the ever expanding number of options for treating cancer and preserving fertility, there is now an opportunity to take a precision medicine approach to informing patients about the fertility risks associated with their cancer treatment and the fertility preservation options that are available to them.",
keywords = "Cancer, Chemo- or radiation therapy, Fertility preservation, Oocyte, Precision medicine, Technologies",
author = "Kim, {So Youn} and Kim, {Seul Ki} and Lee, {Jung Ryeol} and Woodruff, {Teresa K.}",
year = "2016",
month = "3",
doi = "10.3802/jgo.2016.27.e22",
language = "English (US)",
volume = "27",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "2",

}

TY - JOUR

T1 - Toward precision medicine for preserving fertility in cancer patients

T2 - Existing and emerging fertility preservation options for women

AU - Kim, So Youn

AU - Kim, Seul Ki

AU - Lee, Jung Ryeol

AU - Woodruff, Teresa K.

PY - 2016/3

Y1 - 2016/3

N2 - As the number of young cancer survivors increases, quality of life after cancer treatment is becoming an ever more important consideration. According to a report from the American Cancer Society, approximately 810,170 women were diagnosed with cancer in 2015 in the United States. Among female cancer survivors, 1 in 250 are of reproductive age. Anticancer therapies can result in infertility or sterility and can have long-term negative effects on bone health, cardiovascular health as a result of reproductive endocrine function. Fertility preservation has been identified by many young patients diagnosed with cancer as second only to survival in terms of importance. The development of fertility preservation technologies aims to help patients diagnosed with cancer to preserve or protect their fertility prior to exposure to chemo- or radiation therapy, thus improving their chances of having a family and enhancing their quality of life as a cancer survivor. Currently, sperm, egg, and embryo banking are standard of care for preserving fertility for reproductive-age cancer patients; ovarian tissue cryopreservation is still considered experimental. Adoption and surrogate may also need to be considered. All patients should receive information about the fertility risks associated with their cancer treatment and the fertility preservation options available in a timely manner, whether or not they decide to ultimately pursue fertility preservation. Because of the ever expanding number of options for treating cancer and preserving fertility, there is now an opportunity to take a precision medicine approach to informing patients about the fertility risks associated with their cancer treatment and the fertility preservation options that are available to them.

AB - As the number of young cancer survivors increases, quality of life after cancer treatment is becoming an ever more important consideration. According to a report from the American Cancer Society, approximately 810,170 women were diagnosed with cancer in 2015 in the United States. Among female cancer survivors, 1 in 250 are of reproductive age. Anticancer therapies can result in infertility or sterility and can have long-term negative effects on bone health, cardiovascular health as a result of reproductive endocrine function. Fertility preservation has been identified by many young patients diagnosed with cancer as second only to survival in terms of importance. The development of fertility preservation technologies aims to help patients diagnosed with cancer to preserve or protect their fertility prior to exposure to chemo- or radiation therapy, thus improving their chances of having a family and enhancing their quality of life as a cancer survivor. Currently, sperm, egg, and embryo banking are standard of care for preserving fertility for reproductive-age cancer patients; ovarian tissue cryopreservation is still considered experimental. Adoption and surrogate may also need to be considered. All patients should receive information about the fertility risks associated with their cancer treatment and the fertility preservation options available in a timely manner, whether or not they decide to ultimately pursue fertility preservation. Because of the ever expanding number of options for treating cancer and preserving fertility, there is now an opportunity to take a precision medicine approach to informing patients about the fertility risks associated with their cancer treatment and the fertility preservation options that are available to them.

KW - Cancer

KW - Chemo- or radiation therapy

KW - Fertility preservation

KW - Oocyte

KW - Precision medicine

KW - Technologies

UR - http://www.scopus.com/inward/record.url?scp=84955089979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955089979&partnerID=8YFLogxK

U2 - 10.3802/jgo.2016.27.e22

DO - 10.3802/jgo.2016.27.e22

M3 - Review article

C2 - 26768785

AN - SCOPUS:84955089979

VL - 27

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 2

ER -